Scientific credibility
Our leadership and advisory board include globally recognized experts in oncology, diagnostics, and precision medicine. With decades of experience across academia, pharma, and biotech, the team has authored hundreds of publications and led major innovations in cancer research.
Their expertise spans:
- Biomarker discovery
- AI-driven analytics
- Regulatory strategy
- Clinical implementation
This unique blend of scientific rigor and commercial insight positions us at the forefront of next-generation cancer diagnostics.
Expertise That Drives Impact
We unite deep scientific knowledge, clinical excellence, and proven commercial leadership. With global experience and strong regulatory acumen, our team accelerates innovation and delivers measurable impact—benefiting both patients and investors.
Operational team
Managing Director
Melissa Florenova
PhD, EMBA, Interim & Consultant. MSc in Engineering and Biotechnology from the Royal Institute of Technology, PhD in Medical Science (immunology) from Karolinska Institutet and an Executive MBA from the Stockholm School of Economics.
Read more
Melissa combines scientific excellence with strong business acumen. With many years in the pharmaceutical industry and 8 years as an entrepreneur and consultant, she has led strategic initiatives across the entire drug development lifecycle – from preclinical research to commercialization. Her experience spans leadership roles in both start-ups and global corporations, where she has driven business development, market strategies, and organizational growth. Her unique ability to bridge science, business, and sustainability makes her a dynamic leader for innovation-driven companies
Founding member
Rolf Lewensohn
PhD, MD, Professor of Oncology (Karolinska Institutet). Rolf is a Senior Consultant at Karolinska University Hospital with decades of experience in cancer research and clinical oncology
Read more
He has been a key architect of the Personalized Cancer Medicine (PCM) program and a driving force in implementing translational research into clinical practice. As founder of Oncopeptides AB and co-coordinator of the EurocanPlatform, Rolf brings extensive international networks and strong connections to Big Pharma, enabling strategic partnerships and innovation. With over 200 scientific publications and supervision of more than 20 PhD students, he combines academic excellence with practical clinical insight. His expertise spans biomarker development, therapeutic strategies, and companion diagnostics, ensuring that cutting-edge science translates into patient benefit. This unique combination of clinical authority, research leadership, and global industry ties makes him an invaluable advisor for advancing precision oncology and accelerating market adoption.
Founding member
Bo Franzén
PhD and Associate Professor (Karolinska Institutet). Bo is an expert in cancer proteomics and molecular diagnostics with over 30 years of experience spanning academia and the pharmaceutical industry
Read more
He has led research in biomarker discovery, molecular profiling, and precision medicine, including senior roles at AstraZeneca and ongoing work at Karolinska Institutet. His recent focus is on developing fine needle aspiration (FNA)-based sampling combined with multi-omics and AI-driven analytics to advance personalized cancer care. With a strong track record of innovation, clinical integration, and translational research, Bo Franzén brings deep scientific and strategic expertise to next-generation precision diagnostic solutions.
Founding member
Per A. Norell
holds an MBA degree from University of Houston, US, specializing in finance and marketing and a graduate degree in accounting and economics from the University of Stockholm
Read more
Past experience during the years 1985-2011 includes managerial positions within the Ericsson Group in Finance and Marketing. Upon retirement from Ericsson 2011, he served as Financial Manager at the Department of Oncology-Pathology within Karolinska Institutet until 2016. Per Norell has more than 40 years of experience in all aspects of finance. His many years of experience in financial analysis, budgeting, mergers and acquisitions and administration has helped in achieving many financial goals and sound financial investment strategies
Advisory board
Our Advisory Board unites a unique blend of expertise across science, clinical practice, regulation, and commercialization. From world-leading oncologists and pathologists to specialists in AI-driven analytics, regulatory strategy, and global market access, the team brings decades of experience from academia, big pharma, and biotech. Their combined strengths ensure scientific rigor, clinical relevance, and strategic insight – creating a powerful foundation for innovation and growth. This diversity of perspectives positions us to navigate complex challenges and accelerate the adoption of next-generation cancer diagnostics worldwide
Maria Lohm
MSc in Biochemistry and Molecular Biology from Göteborg University, with highly accomplished life science experience and advanced leadership and business training
Read more
She has held senior roles at leading global companies, including Johnson & Johnson, Roche, Pfizer, and AstraZeneca, where she specialised in commercial strategy, market access, branding, and both traditional and digital marketing. Maria’s expertise includes building and developing organisations, driving profitability, and executing go-to-market models tailored to diverse markets. Her strategic skills in business development, organisational growth, and marketing execution have made her a valuable contributor across a range of therapeutic areas.
Anders Hagman
PhD in Analytical Chemistry (Stockholms universitet)
Read more
Anders brings over 30 years of experience in pharmaceutical and biotech development, spanning from discovery to late clinical phases (e.g. Cobra Biologics, AstraZeneca, Pharmacia & Upjohn). He has deep expertise in CMC, GMP, quality systems, and regulatory compliance across major authorities including EMA, FDA, and LV. As a former R&D leader and current CMC consultant, he specializes in regulatory documentation, audits, and implementation of compliance frameworks for clinical trials and manufacturing. His strong background in bridging science, quality, and regulation makes him a key asset for guiding strategy in highly regulated environments.
Gabriella Ödman
MSc in Economics and Business Management (Stockholms universitet)
Read more
Gabriella Ödman brings a unique combination of strategic thinking, practical business experience, and international outlook, making her a valuable member of a Commercial Advisory Board. With over 15 years in the optical industry and solid experience in pharmaceuticals and life sciences (e.g. AstraZeneca), she excels at turning research and innovation into commercial success. Her strengths include building business models, driving market expansion, and creating bridges between academia, clinics, and industry. Combined with strong communication skills and global perspective, she adds significant value to innovation-driven organizations.
Sven P. Jacobsson
Professor emeritus and PhD in Analytical Chemistry (Stockholm University)
Read more
Sven P. Jacobsson combines a strong scientific foundation in mathematics and chemistry with over 40 years of experience applying advanced analytics to life sciences. His expertise spans machine learning, deep learning, and predictive modeling, enabling data-driven insights. With a background in big pharma (AstraZeneca) and as a founder of multiple life science companies (e.g. ClinStorage), he brings a unique perspective on integrating AI and digital technologies into precision medicine. This blend of scientific rigor, digital innovation, and entrepreneurial experience makes him a key advisor for next-generation healthcare solutions.
Gert Auer
Professor Emeritus and MD, an internationally recognized cytopathologist with over five decades of pioneering work in cancer diagnostics and molecular pathology
Read more
He played a key role in advancing fine needle aspiration (FNA) techniques and integrating molecular profiling into clinical practice, significantly improving patient care worldwide. Gert Auer has more than 400 publications and as a mentor to numerous PhD students, he has shaped both scientific progress and the next generation of cancer specialists. His leadership in translational research and global collaborations continues to influence precision oncology and minimally invasive diagnostics.